BIGG

Resultados: 6

Enfermedad meningocócica: guía de práctica clínica
Meningococcal disease: clinical practice guideline

Generar recomendaciones basadas en la mejor evidencia disponible acerca de la prevención y tratamiento de Enfermedad Meningocócica. Toda persona, niño o adulto, con sospecha o diagnóstico de Enfermedad Meningocócica, atendidos en cualquiera de los niveles de atención, ambulatorios y hospitalizado...

The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults

J. infect; 72 (4), 2016
Bacterial meningitis and meningococcal sepsis are rare conditions with high case fatality rates. Early recognition and prompt treatment saves lives. In 1999 the British Infection Society produced a consensus statement for the management of immunocompetent adults with meningitis and meningococcal sepsis. ...

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults (Including College Students)

MMWR recomm. rep; 64 (41), 2015
Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose serie...

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal Disease

MMWR recomm. rep; 64 (22), 2015
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®...

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Infant Meningococcal Vaccines

MMWR recomm. rep; 62 (RR02), 2013
Two meningococcal vaccines, MenACWY-D and Hib-MenCY-TT, were licensed for use in infants in April 2011 and June 2012, respectively. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods[1]. The primary policy question was “Should men...

Guía de práctica Clínica sobre el manejo de la enfermedad meningócocica invasiva

Optimizar el manejo clínico de la EMI en la población infantojuvenil, con recomendaciones orientadas a lograr la detección precoz y una rápida instauración del tratamiento que permitan reducir la elevada morbilidad y mortalidad asociadas a la enfermedad; Ofrecer a los profesionales sanitarios que de...